☆ 4.4 Review

Donor-Derived Cell-free DNA for Personalized Immunosuppression in Renal Transplantation

THERAPEUTIC DRUG MONITORING (2023)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies

Philip F. Halloran et al.

Summary: The donor-derived cell-free DNA fraction (dd-cfDNA[%]) in plasma at the time of indication biopsy is strongly correlated with gene expression in the biopsied allograft, particularly in cases of active molecular rejection. This correlation has the potential to reduce unnecessary biopsies in kidney transplant recipients.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Article Immunology

Graft-derived Cell-free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: A Cohort Study on Clinical Validity and Confounding Factors

Franziska Knuettgen et al.

Summary: Circulating graft-derived cell-free DNA (dd-cfDNA) is a promising marker for diagnosing cardiac rejection in heart transplant recipients. This study found that dd-cfDNA plasma values were significantly associated with rejection, although factors such as pericardial effusions and improper sampling should be considered when interpreting the results.

TRANSPLANTATION (2022)

Add to Collection

Letter Transplantation

Donor-derived Cell-free DNA as a Graft Injury Marker Following Kidney Transplantation

Ryan Lane et al.

TRANSPLANTATION DIRECT (2022)

Add to Collection

Article Medicine, Research & Experimental

Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients

Eva Schrezenmeier et al.

Summary: Transplant recipients may have impaired immunity after SARS-CoV-2 vaccination due to immunosuppression caused by mycophenolate (MPA). Temporary MPA hold has been shown to greatly improve the outcomes of booster vaccination in these patients.

JCI INSIGHT (2022)

Add to Collection

Article Surgery

Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers

Chethan M. Puttarajappa et al.

Summary: The study found that screening for subclinical rejection more than once during the first year after kidney transplantation is not economically reasonable, with a one-time screening at peak incidence being the preferred option. Screening with protocol biopsy was favored over using biomarkers.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Review Immunology

The Monitoring of Donor-derived Cell-free DNA in Kidney Transplantation

Edward John Filippone et al.

Summary: Cell-free DNA (cfDNA) in solid organ transplantation can be used as a noninvasive method to identify acute rejection, with the potential for early detection of subclinical rejection in stable patients. However, levels of donor-derived cfDNA (ddcfDNA) are influenced by various factors and cannot completely replace traditional biopsy for diagnosis. Further randomized controlled trials are needed to validate the efficacy and cost-effectiveness of using cfDNA for monitoring rejection in organ transplant patients.

TRANSPLANTATION (2021)

Add to Collection

Article Immunology

Diagnostic Accuracy of Donor-derived Cell-free DNA in Renal-allograft Rejection: A Meta-analysis

Hanyu Xiao et al.

Summary: Donor-derived cell-free DNA can be a useful marker for diagnosing AMR in recipients with suspected renal dysfunction, but its diagnostic accuracy for MRE remains uncertain and requires further prospective, large-scale, multicenter, and common population research.

TRANSPLANTATION (2021)

Add to Collection

Editorial Material Medical Laboratory Technology

Molecular Approaches to Transplant Monitoring; Is the Horizon Here?

Sean Agbor-Enoh et al.

CLINICAL CHEMISTRY (2021)

Add to Collection

Article Surgery

OPTN/SRTR 2019 Annual Data Report: Kidney

A. Hart et al.

Summary: Despite the ongoing increase in kidney transplants and relatively stable number of patients waiting for a transplant, only a quarter of waitlisted patients receive a deceased-donor kidney transplant within five years.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Review Immunology

Donor-derived Cell-free DNA in Solid-organ Transplant Diagnostics: Indications, Limitations, and Future Directions

Ashish Kataria et al.

Summary: Recent years have seen significant growth in clinical research on the use of donor-derived cell-free DNA (dd-cfDNA) in solid-organ transplants (SOT). While initially studied as a means of detecting allograft rejection, it is now considered more of an indicator of the severity of organ damage. Multiple studies suggest that dd-cfDNA is effective in diagnosing antibody-mediated rejection but less so for T-cell-mediated rejection.

TRANSPLANTATION (2021)

Add to Collection

Article Urology & Nephrology

Exploring the Complexity of Death-Censored Kidney Allograft Failure

Manuel Mayrdorfer et al.

Summary: The study found that kidney graft loss is often caused by multiple factors and more complex than previously thought, including intercurrent medical events, T cell-mediated rejection, and antibody-mediated rejection; the primary cause is often antibody-mediated rejection.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Review Medical Laboratory Technology

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Stein Bergan et al.

Summary: This report provides an updated and comprehensive presentation of consensus on personalized treatment with MPA, including topics such as analytical criteria, pharmacogenetics, biomarker development, and practical intervention aspects. Graded recommendations on target ranges for selected topics, such as the limited sampling strategies for MPA area under the curve, are included to aid in personalized dosing.

THERAPEUTIC DRUG MONITORING (2021)

Add to Collection

Article Transplantation

Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series

Bilgin Osmanodja et al.

Summary: The debate on whether relative or absolute quantification of dd-cfDNA is more reliable for the detection of acute transplant injury continues. This study found discrepancies in relative and absolute quantification of dd-cfDNA in late posttransplant patients, with reasons including infections, low leukocyte count, and variability in total cfDNA levels. Relying solely on relative dd-cfDNA may lead to false-negative and false-positive results, suggesting the use of both absolute and relative quantification for higher reliability in clinical settings, particularly in patients with chronic active antibody-mediated rejection.

TRANSPLANTATION DIRECT (2021)

Add to Collection

Review Urology & Nephrology

Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury

Michael Oellerich et al.

Summary: Donor-derived cell-free DNA (dd-cfDNA) serves as a potential biomarker in kidney transplantation for early detection and monitoring of rejection, guiding immunosuppressive therapy, and reducing the risk of unnecessary biopsies.

NATURE REVIEWS NEPHROLOGY (2021)

Add to Collection

Review Surgery

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation

Akshta Pai et al.

Summary: Kidney transplant recipients require meticulous monitoring for allograft health, with conventional biomarkers being lagging and invasive. Donor-derived cell-free DNA serves as a sensitive noninvasive indicator for early intervention and improved long-term outcomes in kidney transplantation.

ANNALS OF TRANSPLANTATION (2021)

Add to Collection

Review Immunology

Donor-derived Cell-free DNA in Solid-organ Transplant Diagnostics: Indications, Limitations, and Future Directions

Ashish Kataria et al.

Summary: Recent years have seen a surge in clinical research on the use of donor-derived cell-free DNA (dd-cfDNA) in solid-organ transplants, showing potential in diagnosing rejection reactions. While most studies have focused on kidney transplants, research on other organ transplants is ongoing. Findings indicate that dd-cfDNA can serve as a marker for assessing injury severity, but its specificity in relation to rejection reactions requires further exploration.

TRANSPLANTATION (2021)

Add to Collection

Article Surgery

Quantitative PCR of INDELs to measure donor-derived cell-free DNA-a potential method to detect acute rejection in kidney transplantation: a pilot study

Eva-Maria Dauber et al.

TRANSPLANT INTERNATIONAL (2020)

Add to Collection

Article Cell Biology

A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection

Joshua Y. C. Yang et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Review Immunology

Adding Insult on Injury: Immunogenic Role for Donor-derived Cell-free DNA?

Shamik Dholakia et al.

TRANSPLANTATION (2020)

Add to Collection

Editorial Material Medical Laboratory Technology

The Proportion of Donor-Specific Cell-Free DNA in Blood as a Marker of Transplant Rejection: Not an Absolute

Iwijn De Vlaminck

CLINICAL CHEMISTRY (2020)

Add to Collection

Article Medical Laboratory Technology

Time-Dependent Apparent Increase in dd-cfDNA Percentage in Clinically Stable Patients Between One and Five Years Following Kidney Transplantation

Ekkehard Schutz et al.

CLINICAL CHEMISTRY (2020)

Add to Collection

Review Surgery

Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis

Veerle P. W. M. Wijtvliet et al.

TRANSPLANT INTERNATIONAL (2020)

Add to Collection

Review Medical Laboratory Technology

Donor-Derived Cell-Free DNA Testing in Solid Organ Transplantation: A Value Proposition

Michael Oellerich et al.

JOURNAL OF APPLIED LABORATORY MEDICINE (2020)

Add to Collection

Article Surgery

Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study

Michael Oellerich et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2019)

Add to Collection

Article Medical Laboratory Technology

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

Merce Brunet et al.

THERAPEUTIC DRUG MONITORING (2019)

Add to Collection

Article Surgery

Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction

John B. Whitlam et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2019)

Add to Collection

Review Medical Laboratory Technology

Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy

Michael Oellerich et al.

THERAPEUTIC DRUG MONITORING (2019)

Add to Collection

Article Immunology

Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes

Sandesh Parajuli et al.

TRANSPLANTATION (2019)

Add to Collection

Review Immunology

Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review

Simon Robert Knight et al.

TRANSPLANTATION (2019)

Add to Collection

Article Medicine, General & Internal

Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR

Tara K. Sigdel et al.

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection

Article Surgery

Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients

Edmund Huang et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2019)

Add to Collection

Review Biochemical Research Methods

Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation

Karen Sherwood et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2018)

Add to Collection

Article Multidisciplinary Sciences

Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay

Els M. Gielis et al.

PLOS ONE (2018)

Add to Collection

Article Urology & Nephrology

Cell-Free DNA and Active Rejection in Kidney Allografts

Roy D. Bloom et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

Add to Collection

Article Biochemical Research Methods

Quantification of transplant-derived circulating cell-free DNA in absence of a donor genotype

Eilon Sharon et al.

PLOS COMPUTATIONAL BIOLOGY (2017)

Add to Collection

Article Pathology

Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients

Marica Grskovic et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2016)

Add to Collection

Review Medical Laboratory Technology

Therapeutic Drug Monitoring of Everolimus: A Consensus Report

Maria Shipkova et al.

THERAPEUTIC DRUG MONITORING (2016)

Add to Collection

Review Medical Laboratory Technology

Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation

Merce Brunet et al.

THERAPEUTIC DRUG MONITORING (2016)

Add to Collection

Article Multidisciplinary Sciences

Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments

Kun Sun et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

Add to Collection

Review Pharmacology & Pharmacy

Antibody-Mediated Rejection in Kidney Transplantation: A Review of Pathophysiology, Diagnosis, and Treatment Options

Miae Kim et al.

PHARMACOTHERAPY (2014)

Add to Collection

Article Cell Biology

Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection

Iwijn De Vlaminck et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

Add to Collection

Article Medical Laboratory Technology

Digital Droplet PCR for Rapid Quantification of Donor DNA in the Circulation of Transplant Recipients as a Potential Universal Biomarker of Graft Injury

Julia Beck et al.

CLINICAL CHEMISTRY (2013)

Add to Collection

Review Cardiac & Cardiovascular Systems

Non-invasive approaches for the diagnosis of acute cardiac allograft rejection

Christopher A. Miller et al.

HEART (2013)

Add to Collection

Article Immunology

A Rapid Noninvasive Assay for the Detection of Renal Transplant Injury

Tara K. Sigdel et al.

TRANSPLANTATION (2013)

Add to Collection

Article Multidisciplinary Sciences

Universal noninvasive detection of solid organ transplant rejection

Thomas M. Snyder et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Add to Collection

Letter Surgery

Accumulation of elderly ESRD patients with blood group O on the waiting list

Lutz Liefeldt et al.

TRANSPLANT INTERNATIONAL (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.